+ Watch MNKD
on My Watchlist
A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer.
MNKD appears likely to get the US Food and Drug Administration's approval to market their leading inhalant delivered insulin named Afreeza which is much faster acting than injected insulin in diabetes therapy. Afreeza gets insulin into the bloodstream in about 15 minutes from the lipstick case sized inhaler device whereas needle injected insulin takes 45 minutes or more to begin modulating blood sugar in type II diabetics. Vastly better insulin delivery system in a world with some 370 million diabetics. Huge worldwide market potential.If Afreeza is approved by the Food and Drug regulators share prices could easily triple or more over the next year.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions